INCY Latest Press Releases

-- March 17, 2026 --

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI (tafasitamab) for Follicular Lymphoma in Argentina and Mexico Globe Newswire 7:30 AM

Knight Therapeutics Announces Approval of Additional Indication for MINJUVI (tafasitamab) in Brazil Globe Newswire 7:30 AM

-- March 6, 2026 --

Incyte Announces the European Commission Approval of Zynyz (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) Business Wire 4:42 PM

-- March 2, 2026 --

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight PRNewswire 5:31 PM

-- February 27, 2026 --

Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata PRNewswire 8:12 AM

-- February 19, 2026 --

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Ra, and Others | DelveInsight PRNewswire 5:31 PM

-- February 17, 2026 --

Registration Momentum Builds Across the Oncology Pipeline Globe Newswire 10:48 AM

Incyte to Present at Upcoming Investor Conferences Business Wire 8:00 AM

-- February 16, 2026 --

Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight PRNewswire 5:31 PM

-- February 10, 2026 --

Incyte Reports Fourth Quarter and Full Year 2025 Financial Results Business Wire 7:00 AM

-- January 30, 2026 --

Incyte Announces Positive CHMP Opinion for Zynyz (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) Business Wire 9:29 AM

-- January 27, 2026 --

Incyte to Report Fourth Quarter and Year-End 2025 Financial Results Business Wire 8:00 AM

-- January 5, 2026 --

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi/Minjuvi) as a First-line Treatment for Diffuse Large B-Cell Lymphoma Business Wire 7:30 AM

-- December 22, 2025 --

Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma Business Wire 2:44 AM

Incyte Japan Announces Approval of Zynyz (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer Business Wire 2:42 AM

-- December 18, 2025 --

Incyte to Present at Upcoming Investor Conference Business Wire 8:00 AM

-- December 17, 2025 --

Incyte Announces European Commission Approval of Minjuvi (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma Business Wire 11:20 AM

-- December 12, 2025 --

Incyte Announces Change to its Board of Directors Business Wire 8:30 AM

-- December 8, 2025 --

Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia Business Wire 4:30 PM

-- December 7, 2025 --

Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA Business Wire 9:30 AM

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025 Business Wire 9:30 AM

-- December 3, 2025 --

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- December 2, 2025 --

Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding Business Wire 9:15 AM

-- December 1, 2025 --

Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel Business Wire 8:00 AM

-- November 19, 2025 --

Incyte to Present at Upcoming Investor Conferences Business Wire 8:00 AM

-- November 17, 2025 --

Incyte Announces Positive CHMP Opinion for Minjuvi (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL) Business Wire 1:00 AM

-- November 6, 2025 --

Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema Business Wire 9:15 AM

-- November 4, 2025 --

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors Globe Newswire 7:01 AM

-- November 3, 2025 --

Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting Business Wire 9:31 AM

-- October 30, 2025 --

Incyte to Present at Upcoming Investor Conferences Business Wire 8:00 AM

Knight Therapeutics Announces Approval and Launch of MINJUVI (tafasitamab) in Argentina Globe Newswire 7:30 AM

-- October 28, 2025 --

Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates Business Wire 7:00 AM

-- October 27, 2025 --

Incyte and Enable Injections Announce Strategic Partnership for enFuse On-Body Delivery System Business Wire 7:30 AM

-- October 25, 2025 --

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis Business Wire 7:55 PM

-- October 24, 2025 --

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial PRNewswire 6:45 AM

-- October 19, 2025 --

Incyte Announces Phase 1 Results for its TGFR2PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma Business Wire 1:30 PM